

## **Amondys 45**

## **Prior Authorization Request**

Your patient's benefit plan requires prior authorization for certain medications. In order to make appropriate medical necessity determinations, your patient's diagnosis and other clinical information is required. **Please complete the information requested on the form below and fax this form to Priority Partners, toll-free at 1-866-212-4756** to initiate the review process. If you have questions regarding the prior authorization please contact Priority Partners at 888-819-1043 Option 4.

Patient's Name:	Date:
Patient's ID:	Patient's Date of Birth:
Physician's Name:	<del> </del>
Specialty:	NPI#:
Physician Office Telephone:	Physician Office Fax:
<b>Referring</b> Provider Info: ☐ Same as Requesting Provider	der
Name:	NPI#:
Fax:	Phone:
<b>Rendering</b> Provider Info: □ Same as Referring Provider	er 🗆 Same as Requesting Provider
Name:	NPI#:
Fax:	Phone:
	s in accordance with FDA-approved labeling, widence-based practice guidelines.
Patient Weight:kg	
Patient Height:cm	
Please indicate the place of service for the requested drug  ☐ Ambulatory Surgical (POS Code 24)  ☐ Off Campus Outpatient Hospital (POS Code 19)  ☐ Office (POS Code 11)	☐ Home (POS Code 12) ☐ On Campus Outpatient Hospital (POS Code 22)
Drug Information:  Strength/Measure  Directions(sig)	Route of administration
Dosing frequency	-
Criteria Questions:	
What is the ICD-10 code?	
1. What is the diagnosis?	
☐ Duchenne muscular dystrophy (DMD), <i>Continue to 2</i>	
☐ Other, please specify	No Funth on Overtions
Outer, prease specify	two runner Questions
2. Is the requested drug prescribed by or in consultation v Duchenne muscular dystrophy (DMD)?  ☐ Yes, <i>Continue to 3</i> ☐ No, <i>Continue to 3</i>	with a physician who specializes in the treatment of

Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Amondys 45 SGM 4563-A – 09/2023.



3. Does the patient's dose exceed 30 mg/kg once weekly?  ☐ Yes, Continue to 4  ☐ No, Continue to 4
<ul> <li>4. Is the patient currently receiving treatment with the requested drug?</li> <li>☐ Yes, Continue to 5</li> <li>☐ No, Continue to 6</li> </ul>
5. Was the patient previously established on treatment and is re-starting therapy with the requested drug after administration of gene replacement therapy?  ☐ Yes, Continue to 6 ☐ No, Continue to 15
6. Was genetic testing conducted to confirm the diagnosis of Duchenne muscular dystrophy (DMD)? ☐ Yes, <i>Continue to 7</i> ☐ No, <i>Continue to 7</i>
7. Was genetic testing conducted to identify the specific type of DMD gene mutation? <i>ACTION REQUIRED</i> : If Yes, attach a copy of the genetic testing results. <i>ACTION REQUIRED</i> : Submit supporting documentation ☐ Yes, <i>Continue to 8</i> ☐ No, <i>Continue to 10</i>
8. Please indicate the DMD gene mutation:
☐ Please specify DMD gene mutation, Continue to 9 ☐ Unknown, Continue to 10
<ul> <li>9. Is the DMD gene mutation amenable to exon 45 skipping?</li> <li>☐ Yes, Continue to 10</li> <li>☐ No, Continue to 10</li> </ul>
10. Is the patient able to achieve an average distance of at least 300 meters while walking independently over 6 minutes?  ☐ Yes, Continue to 11 ☐ No, Continue to 11
<ul> <li>11. Will treatment with the requested drug be initiated prior to age 14?</li> <li>☐ Yes, Continue to 12</li> <li>☐ No, Continue to 12</li> </ul>
12. Has the patient previously received gene replacement therapy for DMD (e.g., Elevidys)? ☐ Yes, <i>Continue to 13</i> ☐ No, <i>Continue to 14</i>
13. Has the patient experienced a worsening in clinical status (e.g., decline in ambulatory function) since receiving gene replacement therapy for DMD (e.g., Elevidys)? <i>ACTION REQUIRED</i> : If Yes, please attach medical records confirming a worsening in clinical status since receiving gene therapy. <i>ACTION REQUIRED</i> :

Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Amondys 45 SGM 4563-A - 09/2023.

Submit supporting documentation



☐ Yes, Continue to 14
☐ No, Continue to 14



14. What is the patient's weight in kilograms (kg)?kg, No Further Questions	
15. Has the patient demonstrated a response to therapy as evidenced by remaining ambulatory with or without assistance, not wheelchair dependent)? <i>ACTION REQUIRED</i> : If Yes, attach (e.g., chart notes) of response to therapy. <i>ACTION REQUIRED</i> : Submit supporting documen  ☐ Yes, <i>Continue to 16</i> ☐ No, <i>Continue to 16</i>	documentation
16. What is the patient's weight in kilograms (kg)?kg, No Further Questions	

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by Priority Partners.

## Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Amondys 45 SGM 4563-A - 09/2023.



X	
Prescriber or Authorized Signature	Date (mm/dd/yy)